Αποτελέσματα Αναζήτησης
The integrative recommendations for BRCA testing presented here aim to (1) identify indi- viduals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing
The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast ...
Recent data support that genetic testing should be offered to each patient with breast cancer (newly diagnosed or with a personal history). If genetic testing is performed, such testing should include BRCA1/BRCA2 and PALB2, with other genes as appropriate for the clinical scenario and family history.
This overview of clinical management guidelines is based on this patient’s positive test result for a BRCA2 gene mutation. Unless otherwise stated, medical management guidelines used here are limited to those issued by the National Comprehensive Cancer Network® (NCCN®)1 in the U.S.
1 Δεκ 2021 · PDF | Background Mutations in the genes called BRCA1 and BRCA2 are associated with significantly elevated lifetime risk of developing breast and ovarian... | Find, read and cite all the...
Clinical genetic testing for gene mutations allows more precise identifica-tion of those women who are at an increased risk of inherited breast cancer and ovarian cancer. For these individuals, screening and prevention strategies can be instituted to reduce their risks.
clinicians counsel and offer germline BRCA testing to all ovarian cancer patients and only patients with pathogenic variants or variants of uncertain significant (VUS) are referred to genetics services.
